about
Targeting CDCP1 dimerization in triple-negative breast cancerIntegrated in vivo genetic and pharmacologic screening identifies co-inhibition of EGRF and ROCK as a potential treatment regimen for triple-negative breast cancer.Wnt-beta-catenin pathway signals metastasis-associated tumor cell phenotypes in triple negative breast cancers.IL-17E synergizes with EGF and confers in vitro resistance to EGFR-targeted therapies in TNBC cells.Identification of recurrent BRCA1 mutation and its clinical relevance in Chinese Triple-negative breast cancer cohort.SPARC overexpression in primary tumors correlates with disease recurrence and overall survival in patients with triple negative breast cancer.Targeted therapies in breast cancer: New challenges to fight against resistance.DNA repair genes PAXIP1 and TP53BP1 expression is associated with breast cancer prognosis.A Delphi consensus and open debate on the role of first-line bevacizumab for HER2-negative metastatic breast cancer.Efficacy and Safety of Vinorelbine Plus Cisplatin vs. Gemcitabine Plus Cisplatin for Treatment of Metastatic Triple-Negative Breast Cancer After Failure with Anthracyclines and Taxanes.PP2A as the Main Node of Therapeutic Strategies and Resistance Reversal in Triple-Negative Breast Cancer.Estrogen receptor-α promoter methylation is a biomarker for outcome prediction of cisplatin resistance in triple-negative breast cancer.The Notch Pathway in Breast Cancer ProgressionFR58P1a; a new uncoupler of OXPHOS that inhibits migration in triple-negative breast cancer cells via Sirt1/AMPK/β1-integrin pathway
P2860
Q37262893-E36B9149-D01B-4321-B8FD-23F17F3D4A10Q37536415-143414D3-50E6-4B2C-BC02-96497616376FQ37536500-BF2AC581-3479-4777-83E9-25564CD24572Q37619759-0CCD5DBA-9AD5-4AFD-9A49-F35518A6F148Q37693410-C306CFB9-82F8-4CA1-9662-4CB1D29D2693Q37718256-5C43F5D2-8171-4AB0-B224-5FCA8AC5FE79Q37743048-E2D130BF-9DD2-4C0D-A8DE-53627BB3CD21Q38802323-E3897B0D-A9D7-4D9F-89A2-0E2F583F4C64Q38839151-F4D50912-9064-4DEC-8208-BD9804E64A1EQ42275833-EECDB65F-3A39-4B7E-8C0B-47234B149BC9Q47271622-3414DAD8-74E4-422C-9ED7-58AD01991B17Q49875019-76FEA653-8B9E-42FE-8F55-EA4CF0254AF5Q57109777-D07F2E3E-E6B1-4A1B-BBC2-ECAC0D356972Q58765334-334BFD52-DCAF-4BC1-B671-F1ADADC36398
P2860
description
2015 nî lūn-bûn
@nan
2015 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Targeted Therapies in Triple-Negative Breast Cancer
@ast
Targeted Therapies in Triple-Negative Breast Cancer
@en
Targeted Therapies in Triple-Negative Breast Cancer
@nl
type
label
Targeted Therapies in Triple-Negative Breast Cancer
@ast
Targeted Therapies in Triple-Negative Breast Cancer
@en
Targeted Therapies in Triple-Negative Breast Cancer
@nl
prefLabel
Targeted Therapies in Triple-Negative Breast Cancer
@ast
Targeted Therapies in Triple-Negative Breast Cancer
@en
Targeted Therapies in Triple-Negative Breast Cancer
@nl
P2860
P3181
P356
P1433
P1476
Targeted Therapies in Triple-Negative Breast Cancer
@en
P2093
Frederik Marmé
P2860
P304
P3181
P356
10.1159/000433622
P407
P577
2015-07-01T00:00:00Z